Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart
2012-07-18 · Novo Nordisk A/S · original novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 8 November 2012 to discuss the New Drug Applications (NDA) for the ultra-long-acting insulin degludec and insulin degludec/insulin aspart. Further information: Media: Investors: Mike Rulis Kasper Roseeuw Poulsen Tel: (+45) 3079 3573 Tel: (+45) 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ken Inchausti Jannick Lindegaard Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement No 46 / 2012
The release as fetched from its publisher. novonordisk.com ↗